Elite members get real-time data, technical charting, alerts, and no ads - starting at $24.96/mo.

Try Elite for Free

Satellos Bioscience Inc.

Contributing Author

Recent Articles by Satellos Bioscience Inc.

Oct-05	Satellos Granted Composition of Matter Patent for Forazapadin MSLE -5.29% GlobeNewswire
Sep-30	Satellos Announces Completion of Enrollment in BASECAMP Phase 2 Clinical Trial of Forazapadin for Duchenne Muscular Dystrophy MSLE GlobeNewswire
Sep-24	Satellos Announces FDA Clearance of IND Application for Forazapadin in Facioscapulohumeral Muscular Dystrophy (FSHD) and a Partnership with FSHD Canada Foundation Providing Non-Dilutive Financing to Support Clinical Development MSLE GlobeNewswire
Sep-15	Satellos to Present at the 31st Annual Congress of the World Muscle Society MSLE GlobeNewswire
Sep-09	Satellos Announces Forazapadin as Assigned International Nonproprietary Name for Lead Drug Candidate, SAT-3247 MSLE +9.15% GlobeNewswire
Sep-01	Satellos to Participate in Upcoming Investor Conferences MSLE GlobeNewswire
Aug-13	Satellos Reports Second Quarter 2026 Financial Results and Highlights Company Progress MSLE GlobeNewswire
Jul-08	Satellos Reports Six-Month Interim TRAILHEAD Data Showing Reduced Muscle Fat Fraction, Increased Effort, Stable Strength, Lower CK and Favorable Safety Profile in DMD Adults Treated with SAT-3247 MSLE +9.38% GlobeNewswire
Jun-29	Satellos Receives FDA Fast Track Designation for SAT-3247 for the Treatment of Duchenne Muscular Dystrophy MSLE +11.44% GlobeNewswire
Jun-25	Satellos to Present Clinical Program Updates at ICNMD 2026 MSLE +19.40% GlobeNewswire
Jun-17	Satellos Bioscience Announces Results of Annual Meeting of Shareholders MSLE GlobeNewswire
May-27	Satellos to Participate in Upcoming Investor Conferences MSLE +6.98% GlobeNewswire
May-15	Satellos Reports First Quarter 2026 Financial Results and Highlights Company Progress MSLE GlobeNewswire
Apr-09	Satellos to Present at the Bloom Burton & Co. Healthcare Investor Conference MSLE GlobeNewswire
Mar-27	Satellos Reports 2025 Financial Results and Highlights Recent Company Progress MSLE -10.68% GlobeNewswire
Mar-10	Satellos Presents Interim SAT-3247 Clinical and Biomarker Data in Duchenne Muscular Dystrophy at the 2026 MDA Clinical & Scientific Conference MSLE -18.11% GlobeNewswire

Affiliate • Advertise • API and Exports • Careers • Contact • Blog • Help • Privacy • Follow us on X • Do Not Sell My Personal Information

Stock quotes delayed by 1 minute. Futures and options delayed by 15 minutes.
Copyright © 2007-2026 Finviz.com. All Rights Reserved. Export All Screener Data (CSV)